| NCT06980948 | Safety and Tolerability Study of ST-503 for Small Fiber Neuropathy-associated Refractory Pain | NOT_YET_RECRUITING | PHASE1 | 2025-10 | 2028-07 | 2027-07 |
| NCT04817774 | Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-03-17 | 2025-10-29 | 2024-07-11 |
| NCT04046224 | Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) | COMPLETED | PHASE1, PHASE2 | 2019-07-23 | 2025-04-10 | 2025-04-10 |
| NCT03653247 | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease | COMPLETED | PHASE1, PHASE2 | 2019-03-06 | 2025-07-17 | 2025-07-17 |
| NCT03432364 | A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) | COMPLETED | PHASE1, PHASE2 | 2018-03-29 | 2022-11-17 | 2022-11-17 |
| NCT02702115 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I | TERMINATED | PHASE1, PHASE2 | 2017-05-24 | 2021-11-03 | 2021-11-03 |
| NCT03041324 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II | TERMINATED | PHASE1, PHASE2 | 2017-05-11 | 2021-05-07 | 2021-05-07 |
| NCT02695160 | Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B | TERMINATED | PHASE1 | 2016-11-15 | 2021-04-19 | 2021-04-19 |
| NCT02225665 | Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART | COMPLETED | PHASE1, PHASE2 | 2014-08 | 2018-06 | 2018-06 |
| NCT01543152 | Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T | COMPLETED | PHASE1, PHASE2 | 2011-12 | 2017-07-07 | 2017-07-07 |
| NCT01252641 | Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects | COMPLETED | PHASE1, PHASE2 | 2010-11 | 2015-05 | 2014-12 |
| NCT01044654 | Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients | COMPLETED | PHASE1 | 2009-12 | 2014-12 | 2014-12 |
| NCT01079325 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | COMPLETED | PHASE2 | 2009-11 | 2016-04 | 2015-05 |
| NCT00985517 | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease | COMPLETED | PHASE1, PHASE2 | 2009-10-29 | 2017-11-16 | 2014-11-09 |
| NCT00876863 | Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease | COMPLETED | PHASE2 | 2008-11 | 2015-08-13 | 2015-08-13 |
| NCT00748501 | Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | PHASE2 | 2008-09 | 2010-06 | 2010-06 |
| NCT00665145 | Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 | COMPLETED | PHASE2 | 2008-01 | 2009-10 | 2009-10 |
| NCT00476931 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | COMPLETED | PHASE2 | 2007-05 | 2010-12 | 2010-07 |
| NCT00400634 | Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease | COMPLETED | PHASE2 | 2006-11 | 2008-11 | 2008-11 |
| NCT00406458 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | COMPLETED | PHASE2 | 2006-11 | 2009-05 | 2008-12 |
| NCT00252850 | Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease | COMPLETED | PHASE1 | 2005-06 | 2007-03 | 2007-03 |
| NCT00110500 | Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy | COMPLETED | PHASE1 | 2005-04 | 2008-01 | 2008-01 |
| NCT00087789 | CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease | COMPLETED | PHASE1 | 2004-06 | 2010-05 | 2010-05 |